Successful Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma with Denileukin Diftitox.
Successful Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma with Denileukin Diftitox.
复制标题
DOI：
10.1159/000526312
复制
发表时间：
2022-05
影响因子：
0.8
通讯作者：
Fujimura, Taku
中科院分区：
文献类型：
--
作者：
Amagai, Mayuko;Furudate, Sadanori;Ohuchi, Kentaro;Takahashi, Toshiya;Yamazaki, Emi;Chiba, Hiromu;Asano, Yoshihide;Fujimura, Taku
原发性皮肤间变性大细胞淋巴瘤（PCALCL）是一种罕见的皮肤T细胞淋巴瘤（CTCL），其特征是cd30表达的大型非典型细胞具有肾状细胞核，称为标志细胞。由于PCALCL是一种罕见的CTCL变体，PCALCL的治疗仍然存在争议。在这个报告中，一个病例的PCALCL成功地治疗了德尼白素作为二线治疗描述。有趣的是，给药脱白细胞能降低CD8+ T细胞、CD25+细胞、携带颗粒蛋白的淋巴细胞和CD163+巨噬细胞。本病例提示脱白素可能在调节肿瘤微环境的同时具有抗淋巴瘤的作用。
Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare variant of cutaneous T cell lymphoma (CTCL) characterized by CD30-expressing large atypical cells with kidney-shaped nuclei called hallmark cells. Since PCALCL is a rare variant of CTCL, the treatment of PCALCL is still controversial. In this report, a case of PCALCL successfully treated with denileukin diftitox as second-line therapy is described. Interestingly, the administration of denileukin diftitox decreased CD8+ T cells, CD25+ cells, granulysin-bearing lymphocytes, and CD163+ macrophages. The present case suggests that denileukin diftitox might induce an anti-lymphoma effect as well as modulate the tumor microenvironment.
登录
查看更多内容
ALK 阴性间变性大细胞淋巴瘤：异质性大 T 细胞淋巴瘤的当前概念和分子发病机制。
影响因子：
5.2
作者：
Pina-Oviedo S;Ortiz-Hidalgo C;Carballo-Zarate AA;Zarate-Osorno A
通讯作者：
Zarate-Osorno A
影响因子：
45.3
作者：
Prince, H. Miles;Duvic, Madeleine;Negro-Vilar, Andres
通讯作者：
Negro-Vilar, Andres
影响因子：
2.6
作者：
Fierro, MT;Quaglino, P;Bernengo, MG
通讯作者：
Bernengo, MG
影响因子：
3.6
作者：
Fujimura, Taku;Okabe, Takahiro;Aiba, Setsuya
通讯作者：
Aiba, Setsuya
影响因子：
5.7
作者：
Kawai H;Ando K;Maruyama D;Yamamoto K;Kiyohara E;Terui Y;Fukuhara N;Miyagaki T;Tokura Y;Sakata-Yanagimoto M;Igarashi T;Kuroda J;Fujita J;Uchida T;Ishikawa T;Yonekura K;Kato K;Nakanishi T;Nakai K;Matsunaga R;Tobinai K
通讯作者：
Tobinai K